De novo cryptogenic hepatitis after sustained eradication of hepatitis C following liver transplantation

The results of a retrospective analysis of the experience of three Russian regional liver transplantation centers in relation to antiviral therapy of recurrent hepatitis C in liver recipients are presented. There were studied six different therapeutic schedules with direct antiviral drugs (DAVD) administered in 91 patients. The frequency of the persistent virologic response in 12 weeks after the completion of therapy (PVR12) amounted to 92.3%. In recipients, the use of a combination of sofosbuvir and daclatasvir seems to be the most promising as following its administration relapses observed in only 3 out of the 57 recipients were associated with drug resistance mutations to NS5A inhibitors. There were no serious adverse events related to the use of DAVD. The frequency of the reactivation of HBV infection against the background of DAVD therapy in liver recipients did not exceed the previously reported frequency of de novo hepatitis B in non-endemic regions. In recurrent hepatitis C patients after the liver transplantation effects of both the virus genotype, the pronouncement of graft fibrosis and the addition of ribavirin, on the frequency of SVO12 have not been revealed.

Download Full-text

DE NOVO HEPATITIS C DECREASES PATIENT SURVIVAL AFTER LIVER TRANSPLANTATION.

Transplantation Journal ◽

10.1097/00007890-200004271-00776 ◽

2000 ◽

Vol 69 (Supplement) ◽

pp. S314

Author(s):

Elisa Prados ◽

Sonia Garcia-Vizuete ◽

Angel Garcia-Villalon ◽

Jose M. Moreno ◽

Clara Salas ◽

...

Keyword(s):

Liver Transplantation ◽

Hepatitis C ◽

Patient Survival ◽

De Novo

Download Full-text

The Impact of Sirolimus on hepatitis C Recurrence after Liver Transplantation

Canadian Journal of Gastroenterology ◽

10.1155/2011/201019 ◽

2011 ◽

Vol 25 (1) ◽

pp. 28-34 ◽

Cited By ~ 35

Author(s):

Sonal Asthana ◽

Christian Toso ◽

Glenda Meeberg ◽

David L Bigam ◽

Andrew Mason ◽

...

Keyword(s):

Liver Transplantation ◽

Liver Disease ◽

Hepatitis C ◽

Patient Survival ◽

De Novo ◽

Survival Rates ◽

Area Under The Curve ◽

Immunosuppressive Drugs ◽

Initial Recurrence ◽

The Impact

BACKGROUND: While some immunosuppression strategies may accelerate hepatitis C virus (HCV) recurrence after liver transplantation (LT), the impact of sirolimus (SRL) is not known.OBJECTIVE: To assess the risk of biopsy-proven HCV recurrence and patient survival using known and suspected risk factors for HCV recurrence as covariates.METHODS: A retrospective analysis of 141 consecutive patients, including 88 who received de novo SRL therapy, who had undergone a first LT for HCV cirrhosis was conducted. Known and suspected risk factor covariates including transplant era, donor and recipient age, Model for End-stage Liver Disease score, cold ischemia time, immunosuppressive drugs and steroid treatment rejection rates were used in the assessment.RESULTS: Overall, 72.3% of the cohort developed biopsy-proven HCV recurrence. The incidence of HCV recurrence was not significantly different for patients treated with SRL (75% versus 69.8%; P=0.5). There was no difference found for time to recurrence, nor did mean activity or fibrosis scores differ at the time of initial recurrence. However, on follow-up using serial biopsies in patients with recurrence, the mean activity and fibrosis scores were significantly lower in the SRL group. Donor age and acute rejection episodes were the only factors affecting the HCV recurrence rate (expB 1.02 [95% CI 1.01 to 1.03]); P=0.03; and expB 2.8 [95% CI 1.8 to 4.3]; P<0.01], respectively). SRL treatment did not alter patient survival rates. Among patients treated with SRL-based immunosuppression, higher drug area under the curve levels were associated with a trend to lower disease activity and fibrosis at diagnosis; however, higher SRL levels were associated with shorter recurrence-free survival (P=0.038).CONCLUSION: Results of the present analysis suggest that de novo SRL-based immunosuppression can be safely used in patients undergoing LT for HCV-associated liver disease; however, SRL-based immunosuppression did not significantly affect the timing or severity of post-transplant HCV recurrence. HCV recurrence in SRL-treated patients had lower progressive activity and fibrosis levels on serial biopsy.

Download Full-text

De novo autoimmune hepatitis subsequent to switching from type 2b to type 2a alpha-pegylated interferon treatment for recurrent hepatitis C after liver transplantation: Report of a case

Surgery Today ◽

10.1007/s00595-010-4392-z ◽

2011 ◽

Vol 41 (7) ◽

pp. 1016-1019 ◽

Cited By ~ 8

Author(s):

Kazuki Takeishi ◽

Ken Shirabe ◽

Takeo Toshima ◽

Toru Ikegami ◽

Kazutoyo Morita ◽

...

Keyword(s):

Liver Transplantation ◽

Hepatitis C ◽

Autoimmune Hepatitis ◽

De Novo ◽

Pegylated Interferon ◽

Interferon Treatment ◽

Recurrent Hepatitis ◽

Recurrent Hepatitis C

Download Full-text

De Novo Superinfection of Hepatitis B Virus in an Anti-HBs Positive Patient with Recurrent Hepatitis C Following Liver Transplantation

Gut and Liver ◽

10.5009/gnl.2011.5.2.248 ◽

2011 ◽

Vol 5 (2) ◽

pp. 248-252 ◽

Cited By ~ 1

Author(s):

Sung-Hae Ha ◽

Young-Min Park ◽

Sun-Pyo Hong ◽

So-Ya Back ◽

Soo-Kyeong Shin ◽

...

Keyword(s):

Liver Transplantation ◽

Hepatitis C ◽

Hepatitis B Virus ◽

Hepatitis B ◽

De Novo ◽

Positive Patient ◽

Recurrent Hepatitis ◽

B Virus ◽

Recurrent Hepatitis C

Download Full-text

de novo Autoimmune Hepatitis in a Patient Treated for Recurrent Hepatitis C After Liver Transplantation With Non-interferon-Based Therapy: A Case Report

The American Journal of Gastroenterology ◽

10.14309/00000434-201510001-00741 ◽

2015 ◽

Vol 110 ◽

pp. S325-S326

Author(s):

Aishwarya Kuchipudi ◽

Yakir Muszkat ◽

Yousuf A. Siddiqui ◽

Keith Mullins ◽

Mark Blumenkehl ◽

...

Keyword(s):

Liver Transplantation ◽

Case Report ◽

Hepatitis C ◽

Autoimmune Hepatitis ◽

De Novo ◽

Recurrent Hepatitis ◽

Recurrent Hepatitis C

Download Full-text

Hepatitis C virus recurrence after liver transplantation in Hungary. Trends over the past 10 years

Orvosi Hetilap ◽

10.1556/oh.2013.29647 ◽

2013 ◽

Vol 154 (27) ◽

pp. 1058-1066 ◽

Cited By ~ 2

Author(s):

Fanni Gelley ◽

György Gámán ◽

Zsuzsanna Gerlei ◽

Gergely Zádori ◽

Dénes Görög ◽

...

Keyword(s):

Liver Transplantation ◽

Hepatitis C Virus ◽

Hepatitis C ◽

Graft Survival ◽

Patient Survival ◽

De Novo ◽

Antiviral Treatment ◽

Survival Rates ◽

Early Recurrence ◽

The Past

Introduction: Management of hepatitis C virus recurrence is a challenge after liver transplantation. Aim: The aim of the authors was to analyse the outcome of liver transplantation performed in hepatitis C virus positive patients during the past ten years and to compare recent data with a previous report of the authors. Method: The authors retrospectively evaluated the data (donors, recipients, perioperative characteristics, patient and graft survival, serum titer of hepatitis C virus RNA, histology) of 409 patients who underwent liver transplantation between 2003 and 2012. Results: 156 patients were transplanted due to hepatitis C virus associated liver cirrhosis (38%). Worse outcome was observed in these patients in comparison to hepatitis C virus negative recipients. The cumulative patient survival rates at 1, 5, and 10 year were 80%, 61%, 51% in the hepatitis C virus positive group and 92%, 85%, 79% in the hepatitis C virus negative group, respectively (p<0.001). The cumulative graft survival rates at 1, 5 and 10 year were 79%, 59% and 50% in hepatitis C virus positive and 89%, 80% and 70% in hepatitis C virus negative patients (p<0.001). Hepatitis C virus recurrence was observed in the majority of the patients (132 patients, 85%), mainly within the first year (83%). The authors observed recurrence within 6 months in 71 patients (56%), and within 3 months in 26 patients (20%). The mean hepatitis C virus recurrence free survival was 243 days. Higher rate of de novo diabetes was detected in case of early recurrence. The cumulative patient survival rates at 1, 3, 5, 10 years were 98%, 89.5%, 81% and 65% when hepatitis C virus recurrence exceeded 3 months and 64%, 53%, 30.5% and 30.5% in patients with early recurrence (p<0.001). Conclusions: Poor outcome of liver transplantation in hepatitis C virus positive patients is still a challenge. Hepatitis C virus recurrence is observed earlier after liver transplantation in comparison with a previous report of the authors. De novo diabetes occurs more frequently in case of early recurrence. Despite an immediate start of antiviral treatment, early recurrence has a significant negative impact on the outcome of transplantation. Orv. Hetil., 2013, 154, 1058–1066.

Download Full-text